NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $2.08 billion. The enterprise value is $1.88 billion.
| Market Cap | 2.08B |
| Enterprise Value | 1.88B |
Important Dates
The last earnings date was Thursday, July 23, 2026, before market open.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 116.45 million shares outstanding. The number of shares has increased by 3.65% in one year.
| Current Share Class | 116.45M |
| Shares Outstanding | 116.45M |
| Shares Change (YoY) | +3.65% |
| Shares Change (QoQ) | +1.63% |
| Owned by Insiders (%) | 8.68% |
| Owned by Institutions (%) | 81.42% |
| Float | 96.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.98 |
| Forward PS | 2.78 |
| PB Ratio | 6.16 |
| P/TBV Ratio | 6.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.69.
| Current Ratio | 2.89 |
| Quick Ratio | 2.66 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.80 |
Financial Efficiency
Return on equity (ROE) is -43.22% and return on invested capital (ROIC) is -114.27%.
| Return on Equity (ROE) | -43.22% |
| Return on Assets (ROA) | -9.26% |
| Return on Invested Capital (ROIC) | -114.27% |
| Return on Capital Employed (ROCE) | -26.32% |
| Weighted Average Cost of Capital (WACC) | 9.45% |
| Revenue Per Employee | $435,634 |
| Profits Per Employee | -$92,564 |
| Employee Count | 1,605 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 4.01 |
Taxes
| Income Tax | -4.12M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +52.91% in the last 52 weeks. The beta is 0.98, so NovoCure's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +52.91% |
| 50-Day Moving Average | 16.45 |
| 200-Day Moving Average | 14.13 |
| Relative Strength Index (RSI) | 56.14 |
| Average Volume (20 Days) | 1,257,841 |
Short Selling Information
The latest short interest is 10.14 million, so 8.71% of the outstanding shares have been sold short.
| Short Interest | 10.14M |
| Short Previous Month | 11.46M |
| Short % of Shares Out | 8.71% |
| Short % of Float | 10.51% |
| Short Ratio (days to cover) | 5.53 |
Income Statement
In the last 12 months, NovoCure had revenue of $699.19 million and -$148.57 million in losses. Loss per share was -$1.31.
| Revenue | 699.19M |
| Gross Profit | 533.98M |
| Operating Income | -151.19M |
| Pretax Income | -152.69M |
| Net Income | -148.57M |
| EBITDA | -136.39M |
| EBIT | -151.19M |
| Loss Per Share | -$1.31 |
Balance Sheet
The company has $440.56 million in cash and $233.42 million in debt, with a net cash position of $207.14 million or $1.78 per share.
| Cash & Cash Equivalents | 440.56M |
| Total Debt | 233.42M |
| Net Cash | 207.14M |
| Net Cash Per Share | $1.78 |
| Equity (Book Value) | 338.09M |
| Book Value Per Share | 2.90 |
| Working Capital | 417.81M |
Cash Flow
In the last 12 months, operating cash flow was -$2.82 million and capital expenditures -$22.62 million, giving a free cash flow of -$25.43 million.
| Operating Cash Flow | -2.82M |
| Capital Expenditures | -22.62M |
| Depreciation & Amortization | 14.79M |
| Net Borrowing | -460.97M |
| Free Cash Flow | -25.43M |
| FCF Per Share | -$0.22 |
Margins
Gross margin is 76.37%, with operating and profit margins of -21.62% and -21.25%.
| Gross Margin | 76.37% |
| Operating Margin | -21.62% |
| Pretax Margin | -21.84% |
| Profit Margin | -21.25% |
| EBITDA Margin | -19.51% |
| EBIT Margin | -21.62% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.65% |
| Shareholder Yield | -3.65% |
| Earnings Yield | -7.13% |
| FCF Yield | -1.22% |
Analyst Forecast
The average price target for NovoCure is $27.14, which is 51.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.14 |
| Price Target Difference | 51.71% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 13.16% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.45 |
| Piotroski F-Score | 3 |